These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35045694)

  • 81. Dynamics of humoral and T-cell immunity after three BNT162b2 vaccinations in adults older than 80 years.
    Romero-Olmedo AJ; Schulz AR; Hochstätter S; Gupta DD; Hirseland H; Staudenraus D; Camara B; Volland K; Hefter V; Sapre S; Krähling V; Müller-Kräuter H; Chung HR; Mei HE; Keller C; Lohoff M
    Lancet Infect Dis; 2022 May; 22(5):588-589. PubMed ID: 35397209
    [No Abstract]   [Full Text] [Related]  

  • 82. Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma.
    Enßle JC; Campe J; Schwenger A; Wiercinska E; Hellstern H; Dürrwald R; Rieger MA; Wolf S; Ballo O; Steffen B; Serve H; Bonig H; Rabenau HF; Widera M; Ciesek S; Metzler IV; Ullrich E
    Blood; 2022 Jan; 139(1):137-142. PubMed ID: 34657156
    [No Abstract]   [Full Text] [Related]  

  • 83. SARS-CoV-2 vaccination in CLL: how often is enough?
    Mellinghoff SC; Cornely OA
    Blood; 2022 Dec; 140(25):2655-2657. PubMed ID: 36548017
    [No Abstract]   [Full Text] [Related]  

  • 84. SARS-CoV-2 mRNA vaccination of aplastic anemia patients is safe and effective.
    Pothast CR; van Dijk K; Pool ES; Halkes CJM; Heemskerk MHM; Tjon JM
    Am J Hematol; 2023 Feb; 98(2):E20-E23. PubMed ID: 36371670
    [No Abstract]   [Full Text] [Related]  

  • 85. COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia.
    Parry H; Bruton R; Roberts T; McIlroy G; Damery S; Sylla P; Dowell AC; Tut G; Lancaster T; Bone D; Willett B; Logan N; Scott S; Hulme S; Jadir A; Amin U; Nicol S; Stephens C; Faustini S; Al-Taei S; Richter A; Blakeway D; Verma K; Margielewska-Davies S; Pearce H; Pratt G; Zuo J; Paneesha S; Moss P
    Cancer Cell; 2022 Jun; 40(6):584-586. PubMed ID: 35588735
    [No Abstract]   [Full Text] [Related]  

  • 86. Plasma EV-miRNAs as Potential Biomarkers of COVID-19 Vaccine Immune Response in Cancer Patients.
    Almeida B; Dias TR; Cruz P; Sousa-Pimenta M; Teixeira AL; Pereira CE; Costa-Silva B; Oliveira J; Medeiros R; Dias F
    Vaccines (Basel); 2024 Jul; 12(8):. PubMed ID: 39203974
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia.
    Ingelman-Sundberg HM; Blixt L; Wullimann D; Wu J; Gao Y; Healy K; Muschiol S; Bogdanovic G; Åberg M; Kjellander C; Grifoni A; Sette A; Aleman S; Chen P; Blennow O; Hansson L; Ljunggren HG; Chen MS; Buggert M; Österborg A
    Haematologica; 2024 Feb; 109(2):646-651. PubMed ID: 37646668
    [No Abstract]   [Full Text] [Related]  

  • 88. COVID-19 vaccine immune response in patients with plasma cell dyscrasia: a systematic review.
    Faizan U; Nair LG; Bou Zerdan M; Jaberi-Douraki M; Anwer F; Raza S
    Ther Adv Vaccines Immunother; 2023; 11():25151355231190497. PubMed ID: 37645011
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2.
    Szabó E; Modok S; Rónaszéki B; Faragó A; Gémes N; Nagy LI; Hackler L; Farkas K; Neuperger P; Balog JÁ; Balog A; Puskás LG; Szebeni GJ
    Front Med (Lausanne); 2023; 10():1176168. PubMed ID: 37529238
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.
    Qin K; Honjo K; Sherrill-Mix S; Liu W; Stoltz RM; Oman AK; Hall LA; Li R; Sterrett S; Frederick ER; Lancaster JR; Narkhede M; Mehta A; Ogunsile FJ; Patel RB; Ketas TJ; Cruz Portillo VM; Cupo A; Larimer BM; Bansal A; Goepfert PA; Hahn BH; Davis RS
    PLoS Med; 2023 Jun; 20(6):e1004157. PubMed ID: 37384638
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination.
    Lee HK; Hoechstetter MA; Buchner M; Pham TT; Huh JW; Müller K; Zange S; von Buttlar H; Girl P; Wölfel R; Brandmeier L; Pfeuffer L; Furth PA; Wendtner CM; Hennighausen L
    Blood Adv; 2023 May; 7(10):2214-2227. PubMed ID: 36630562
    [TBL] [Abstract][Full Text] [Related]  

  • 92. SARS-CoV-2 mRNA vaccination exposes progressive adaptive immune dysfunction in patients with chronic lymphocytic leukemia.
    Qin K; Honjo K; Sherrill-Mix S; Liu W; Stoltz R; Oman AK; Hall LA; Li R; Sterrett S; Frederick ER; Lancaster JR; Narkhede M; Mehta A; Ogunsile FJ; Patel RB; Ketas TJ; Cruz Portillo VM; Cupo A; Larimer BM; Bansal A; Goepfert PA; Hahn BH; Davis RS
    medRxiv; 2022 Dec; ():. PubMed ID: 36597532
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis.
    Uaprasert N; Pitakkitnukun P; Tangcheewinsirikul N; Chiasakul T; Rojnuckarin P
    Blood Cancer J; 2022 Dec; 12(12):173. PubMed ID: 36550105
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion.
    Shen Y; Freeman JA; Holland J; Naidu K; Solterbeck A; Van Bilsen N; Downe P; Kerridge I; Wallman L; Akerman A; Aggarwal A; Milogiannakis V; Martins Costa Gomes G; Doyle CM; Sandgren KJ; Turville S; Cunningham AL; Mulligan SP
    Blood; 2022 Dec; 140(25):2709-2721. PubMed ID: 36206503
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Comprehensive analysis of immune responses in CLL patients after heterologous COVID-19 vaccination.
    Lee HK; Hoechstetter MA; Buchner M; Pham TT; Huh JW; Müller K; Zange S; von Buttlar H; Girl P; Wölfel R; Brandmeier L; Pfeuffer L; Furth PA; Wendtner CM; Hennighausen L
    medRxiv; 2022 Sep; ():. PubMed ID: 36172132
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination.
    Blixt L; Gao Y; Wullimann D; Murén Ingelman-Sundberg H; Muschiol S; Healy K; Bogdanovic G; Pin E; Nilsson P; Kjellander C; Grifoni A; Sette A; Sällberg Chen M; Ljunggren HG; Buggert M; Hansson L; Österborg A
    Blood; 2022 Dec; 140(22):2403-2407. PubMed ID: 36150168
    [No Abstract]   [Full Text] [Related]  

  • 97. SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia.
    Mellinghoff SC; Mayer L; Robrecht S; Weskamm LM; Dahlke C; Gruell H; Schlotz M; Vanshylla K; Schloser HA; Thelen M; Fink AM; Fischer K; Klein F; Addo MM; Eichhorst B; Hallek M; Langerbeins P
    Haematologica; 2022 Oct; 107(10):2480-2484. PubMed ID: 35734927
    [No Abstract]   [Full Text] [Related]  

  • 98. T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial.
    Blixt L; Wullimann D; Aleman S; Lundin J; Chen P; Gao Y; Cuapio A; Akber M; Lange J; Rivera-Ballesteros O; Buggert M; Ljunggren HG; Hansson L; Österborg A
    Haematologica; 2022 Apr; 107(4):1000-1003. PubMed ID: 35045694
    [No Abstract]   [Full Text] [Related]  

  • 99. Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia.
    Herishanu Y; Avivi I; Levi S; Shefer G; Bronstein Y; Moshiashvili MM; Ziv T; Scarfò L; Perry C; Ghia P
    Blood Adv; 2022 Jan; 6(1):148-151. PubMed ID: 34614513
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.